Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 janv. 2026 19h00 HE | Source: Psyence Biomedical Ltd.

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation...
12 janv. 2026 08h30 HE | Source: Psyence Biomedical Ltd.

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
12 janv. 2026 08h00 HE | Source: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current...
08 janv. 2026 07h00 HE | Source: Transpire Bio

Transpire Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Transpire Bio CEO Dr. Xian-Ming Zeng will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026
07 janv. 2026 08h00 HE | Source: BGB Communications, LLC, dba BGB Group

BGB Group Acquires Hayden Consulting Group to Bolster Market Access and Patient Services

BGB Group strengthens pharma commercialization capabilities by integrating Hayden's payer and reimbursement expertise into its advisory practice.
06 janv. 2026 07h00 HE | Source: Transpire Bio

Transpire Bio Announces Completion of First Human Dosing in Clinical Trial Using its Novel Inhalation Formulation

Transpire Bio today announced that it successfully dosed the first human subject with its experimental drug candidate in a novel inhalation formulation.
23 déc. 2025 05h00 HE | Source: InnoCare Pharma

InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus

CLE is the second indication InnoCare is developing for ICP-488, and enrollment for the phase III study of ICP-488 for psoriasis is nearing completion.
19 déc. 2025 07h00 HE | Source: Psyence Biomedical Ltd.

Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial

NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
17 déc. 2025 15h00 HE | Source: KreaMedica

New Ebook Offers First-Time Biotech CEOs a Roadmap for the Decisions That Determine Company Success

Industry experts launch a free Ebook to help first-time biotech CEOs navigate funding, strategy, partnerships and the decisions that define success.
17 déc. 2025 06h45 HE | Source: kneat.com, inc.

Global Specialty Chemicals Leader Chooses Kneat for Digital Validation

Strategic win of European chemicals leader fuels record growth in Kneat's new customer additions for 2025

Page suivante